NEW DELHI – In what may end up as a landmark $1.3 billion deal, China’s Shanghai Fosun Pharmaceutical (Group) Ltd. is set to acquire Indian injectables specialist Gland Pharma Ltd.
NEW DELHI – In what may end up as a landmark $1.3 billion deal, China’s Shanghai Fosun Pharmaceutical (Group) Ltd. is set to acquire Indian injectables specialist Gland Pharma Ltd.
HYDERABAD, India – Following feedback from industry, health policy experts and the public, India recently updated its draft guidelines for biosimilars, narrowing down the conditions for waivers of late-stage trials and expanding some testing criteria.
HYDERABAD, India – Following feedback from industry, health policy experts and the public, India recently updated its draft guidelines for biosimilars, narrowing down the conditions for waivers of late-stage trials and expanding some testing criteria.
NEW DELHI – Working with a U.S. partner, one of India's most active biopharma companies, Biocon Ltd., is moving forward on late-stage trials for a drug aimed at treating a common eye disorder for which there is no marketed treatment.
NEW DELHI – Working with a U.S. partner, one of India's most active biopharma companies, Biocon Ltd., is moving forward on late-stage trials for a drug aimed at treating a common eye disorder for which there is no marketed treatment.
NEW DELHI – India’s revised draft guidelines for biosimilars have drawn mixed reactions. The country’s pharma industry has, in broad strokes, welcomed the increased clarity and more rigorous conditions in the revised guidelines, but the Organisation of Pharmaceutical Producers of India, comprising largely foreign pharma firms, said the new rules could compromise patient safety.
